Overall, unconfirmed response or stable disease for more than 6 months was observed in 5 (25 %) and 1 (3 %) patient(s) with FGFR1-amplified and FGFR1-nonamplified breast cancers, respectively. The gene discussed is FGFR1; the disease is breast cancer.